Understanding the interplay of
tumor, patient and therapy

to achieve improved
therapeutic outcomes

Exploring the interplay of
tumor, patient and therapy

For cancer patients,
time is of the essence

According to a recent peer-reviewed study focusing on five common cancers (bladder, breast, colon, rectum, and lung), patients whose cancer treatment is delayed by even one month have, in many cases, a 6-13% higher risk of metastasis, which will ultimately result in death. This risk increases with each passing month. It’s clear that every day counts.

Immunotherapy is a
revolution, but only for
the minority who

Over the last decade, anti-PD-1/PD-L1 immunotherapy has emerged as the standard-of-care treatment for NSCLC. Although anti-PD-1/PD-L1 immunotherapy achieves impressive long-term survival in some, the overall response rate is modest, ranging from 20-50% in NSCLC patients. A significant proportion of patients display innate resistance to immunotherapy and many who derive initial clinical benefit experience disease progression at a later stage. The mechanisms underlying innate and acquired resistance to anti-PD-1/PD-L1 treatments are not yet fully understood.

Many combination
protocols are studied,
but biomarker discovery
lags behind

As of early 2021, there were 2,250 active lung cancer clinical trials registered at ClinicalTrials.gov. The potential insights and findings from these clinical trials could be lifesaving, paving a clearer path to improved NSCLC treatments. Alternatively, they may result in a handful of new drugs that demonstrate efficacy in all-comers populations, in some cases with very low response rates.

Better biomarkers are
desperately needed,

but not all biomarkers
are created equal

Most precision oncology tools focus on the contribution of intrinsic changes that predict drug resistance, such as genetic mutations and epigenetic alterations within tumor cells.

But a growing body of evidence demonstrates that cancer and its potential therapy can induce a range of systemic biological processes and molecular changes that enter an interplay between the tumor, the patient, and the therapy.

This interaction can promote tumor regrowth and metastasis through angiogenesis, immune modulation, and other resistance-associated mechanisms, thereby partially or completely negating the intended therapeutic activity.

OncoHost is taking a different approach to precision medicine
by analyzing the interplay between the tumor, the patient, and the therapy on a proteomic level, which allows for a comprehensive and holistic view.

How it works

Pre-treatment blood test
proteomic assay
Bioinformatics and
machine learning
Protein level resistance map: A truly personalized, actionable, and comprehensive disease map

Our proteomics lab

All PROphet® testing is performed at the OncoHost CLIA-certified laboratory in Cary, North Carolina. Our lab uses high-throughput protein analysis technology to quantify the levels of thousands of proteins in a single plasma sample. The proteins include cytokines, chemokines, growth factors, and enzymes associated with therapy resistance and tumor spread.

Contact us

US office

1110 SE Cary Parkway, Suite 205
Cary, North Carolina
T. (855) 950-2112
E. contact@oncohost.com

Israel office

17 Hamelacha Street, Floor 1
Binyamina, Israel
T. +972 485 37558
E. contact@oncohost.com

Please Note:
PROphet® NSCLC is currently available in all US states except NY